Testing lepodisiran to reduce heart plaque buildup
Part of Heart & circulation clinical trials.
This study tests whether a new medicine called lepodisiran can shrink plaque in heart arteries for adults with high Lp(a) (a type of cholesterol linked to heart disease) who have had a heart event or are at serious risk. The trial uses CT scans to monitor changes in your arteries.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your Lp(a) level must be 175 nmol/L or higher (a specific type of cholesterol that increases heart disease risk)
- You must have either had a heart attack, stroke, or other heart event, or be at high risk for one
- A CT scan of your heart (CCTA) must show you have plaque buildup in your coronary arteries
- If you take cholesterol medications like statins, niacin, or PCSK9 inhibitors, you must have been on them for at least 8 weeks without changes
- You cannot have had a major heart event within the past 60 days before enrollment
- You must be able to safely have a CT scan (no allergies to contrast dye, no certain devices, no kidney problems)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how a type of fat in the blood called lipoprotein(a) and your body's ability to break down clots affect heart disease or heart valve disease. It is for people who are already taking certain cholesterol-lowering medicines or have severe aortic valve narrowing from calcium buildup.
This study uses a heart CT scan to look for early signs of heart disease in first-degree relatives of people with high or low Lp(a). It aims to find hidden risks before symptoms start.
This trial tests two experimental drugs designed to lower lipoprotein(a)—a type of cholesterol particle linked to heart disease—in people whose levels remain high despite taking statins (cholesterol-lowering medications). The goal is to see if these drugs can safely reduce this risk factor.
This trial tests a new drug called AZD4954 for safety. It includes healthy volunteers and people with high Lp(a) or dyslipidemia. The goal is to see if the drug is safe and how the body processes it.
This study tests if a medication called olpasiran can lower a type of fat in your blood called Lp(a), which is linked to heart problems. You take the medicine or a placebo and get a special heart scan to see changes in your arteries.
This study looks at levels of a type of cholesterol called Lp(a) in people with certain heart and blood vessel diseases. The goal is to understand how common high Lp(a) is in Russian adults with these conditions.
Hear when a new Atherosclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.